We rank companies based on fund manager, research analyst and news sentiment
BCEL stock icon



About: Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Employees: 90

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

7% less funds holding

Funds holding: 44 [Q3] → 41 (-3) [Q4]

9.7% less ownership

Funds ownership: 38.1% [Q3] → 28.4% (-9.7%) [Q4]

25% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 12

62% less capital invested

Capital invested by funds: $3.24M [Q3] → $1.23M (-$2.01M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for BCEL.

Financial journalist opinion